关键词: 冠心病, 丝氨酸蛋白酶抑制剂, 生长停滞特异性基因产物6, 缺血修饰蛋白

Abstract: ObjectiveTo observe the clinical significance of visceral fatspecific serine protease inhibitors (Vaspin)， growth arrestspecific gene product 6 (Gas6) and ischemiamodified protein (IMA) in assessment of coronary heart disease（CHD）. MethodsA total of 121 patients with CHD， were selected as CHD group and 30 healthy people were chosen during the same period as healthy control group. The levels of serum Vaspin， Gas6 and IMA were detected by ELISA. The serum levels of Vaspin， Gas6 and IMA were compared between CHD group and healthy control group， the relationship among Vaspin， Gas6 and IMA， severity CHD， number of coronary artery atherosclerosis and degree of stenosis were observed in patients with CHD， and the mutual relationship was also observed. ResultsThe level of serum Vaspin was significantly lower in CHD group compared with that of healthy control group (P<0.01)， and the level of Vaspin decreased， as CHD raised， the number of coronary artery atherosclerosis and the degree of stenosis increased (P<0.01)， the serum Gas6 and IMA levels were significantly higher in CHD group than those in healthy control group (P<0.01)， and the level of Vaspin increased， as CHD severity， the number of coronary artery atherosclerosis and the degree of stenosis increased (P<0.01) . The level of serum Vaspin was negatively correlated with Gas6 (r=-0.562，P<0.05) and IMA (r=-0.756，P<0.05) in patients with CHD， and the Gas6 level was positively correlated to IMA (r=0.812，P<0.05). ConclusionThe Vaspin， Gas6 and IMA are involved in the development of CHD， the serum Vaspin， Gas6 and IMA are helpful for early diagnosis of CHD， they have important clinical significance to determine CHD severity and guide the  treatment.

Key words: coronary disease, serine protease inhibitors, growth arrestspecific gene product 6, ischemiamodified protein